Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

(2022) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

(2022) Oliver J. Kennedy et al.   EUROPEAN JOURNAL OF CANCER

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

(2022) Ana Arance et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

(2022) Michael B. Atkins et al.   JOURNAL OF CLINICAL ONCOLOGY

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

(2021) Diwakar Davar et al.   SCIENCE

Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma

(2021) Robert H. I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial

(2021) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma

(2021) Jeffrey S. Weber et al.   EUROPEAN JOURNAL OF CANCER

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

(2021) Julie Westerlin Kjeldsen et al.   NATURE MEDICINE

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

(2021) Walter J Storkus et al.   Journal for ImmunoTherapy of Cancer

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

(2021) Craig L Slingluff et al.   Journal for ImmunoTherapy of Cancer

Relevance of Vitamin D in Melanoma Development, Progression and Therapy

(2020) ANNA A. BROŻYNA et al.   ANTICANCER RESEARCH

Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study

(2020) Sanne Huijberts et al.   Future Oncology

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

(2020) Ruth Plummer et al.   BRITISH JOURNAL OF CANCER

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Ralf Gutzmer et al.   LANCET

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

(2020) Reinhard Dummer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The glutaminase inhibitor CB-839 (Telaglenastat) enhances the anti-melanoma activity of T cell mediated immunotherapies.

(2020) Sruthy Varghese et al.   MOLECULAR CANCER THERAPEUTICS

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

(2019) Robert H. I. Andtbacka et al.   Journal for ImmunoTherapy of Cancer

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

(2019) Georgina V Long et al.   LANCET ONCOLOGY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

(2018) John P. Fruehauf et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T)

(2016) Asad Javed et al.   Future Oncology

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E4697)

(2015) David H. Lawson et al.   JOURNAL OF CLINICAL ONCOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma

(2015) J. J. Luke et al.   Cancer Immunology Research

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

(2015) Zeynep Eroglu et al.   Therapeutic Advances in Medical Oncology

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma

(2014) John F. Thompson et al.   ANNALS OF SURGICAL ONCOLOGY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

(2014) Georgina V. Long et al.   Nature Communications

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

 -Blockers and Survival among Danish Patients with Malignant Melanoma: A Population-Based Cohort Study

(2011) S. Lemeshow et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Key Concepts of Clinical Trials: A Narrative Review

(2011) Craig A. Umscheid et al.   POSTGRADUATE MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE